Experimental and Computational Analysis of Newly Identified Pathogenic Mutations in the Creatine Transporter SLC6A8

  • Evandro Ferrada (Corresponding author)
  • , Tabea Wiedmer
  • , Wen An Wang
  • , Fabian Frommelt
  • , Barbara Steurer
  • , Christoph Klimek
  • , Sabrina Lindinger
  • , Tanja Osthushenrich
  • , Andrea Garofoli
  • , Silvia Brocchetti
  • , Samuel Bradberry
  • , Jiahui Huang
  • , Aidan MacNamara
  • , Lia Scarabottolo
  • , Gerhard F. Ecker
  • , Anders Malarstig
  • , Giulio Superti-Furga

Publications: Contribution to journalArticlePeer Reviewed

Abstract

Creatine is an essential metabolite for the storage and rapid supply of energy in muscle and nerve cells. In humans, impaired metabolism, transport, and distribution of creatine throughout tissues can cause varying forms of mental disability, also known as creatine deficiency syndrome (CDS). So far, 80 mutations in the creatine transporter (SLC6A8) have been associated to CDS. To better understand the effect of human genetic variants on the physiology of SLC6A8 and their possible impact on CDS, we studied 30 missense variants including 15 variants of unknown significance, two of which are reported here for the first time. We expressed these variants in HEK293 cells and explored their subcellular localization and transport activity. We also applied computational methods to predict variant effect and estimate site-specific changes in thermodynamic stability. To explore variants that might have a differential effect on the transporter's conformers along the transport cycle, we constructed homology models of the inward facing, and outward facing conformations. In addition, we used mass-spectrometry to study proteins that interact with wild type SLC6A8 and five selected variants in HEK293 cells. In silico models of the protein complexes revealed how two variants impact the interaction interface of SLC6A8 with other proteins and how pathogenic variants lead to an enrichment of ER protein partners. Overall, our integrated analysis disambiguates the pathogenicity of 15 variants of unknown significance revealing diverse mechanisms of pathogenicity, including two previously unreported variants obtained from patients suffering from the creatine deficiency syndrome.

Original languageEnglish
Article number168383
Number of pages24
JournalJournal of Molecular Biology
Volume436
Issue number2
DOIs
Publication statusPublished - 15 Jan 2024

Funding

This work was performed by the RESOLUTE ( https://re-solute.eu/ ) and REsolution ( https://re-solute.eu/resolution ) consortia. Plasmids are available through Addgene ( https://www.addgene.org/depositor-collections/re-solute/ ). RESOLUTE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. REsolution has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034439. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This article reflects only the authors' views and neither IMI nor the European Union and EFPIA are responsible for any use that may be made of the information contained therein. We thank the Association of Creatine Deficiencies (ACD, http://creatineinfo.org ) for insightful discussions and for providing information of genetic variants from their patient registry.

Austrian Fields of Science 2012

  • 301207 Pharmaceutical chemistry

Keywords

  • creatine
  • creatine deficiency syndrome
  • creatine transporter
  • genetic variants
  • solute carriers

Fingerprint

Dive into the research topics of 'Experimental and Computational Analysis of Newly Identified Pathogenic Mutations in the Creatine Transporter SLC6A8'. Together they form a unique fingerprint.

Cite this